<--- Back to Details
First PageDocument Content
Type 1 hypersensitivity / Tacrolimus / Immune system / Medicine / Atopic dermatitis / Atopy / Interleukin 2 / Immunology / Immunosuppressants / Macrolides
Date: 2013-08-21 15:23:36
Type 1 hypersensitivity
Tacrolimus
Immune system
Medicine
Atopic dermatitis
Atopy
Interleukin 2
Immunology
Immunosuppressants
Macrolides

Add to Reading List

Source URL: www.astellas.us

Download Document from Source Website

Share Document on Facebook

Similar Documents

Clinical medicine / Medicine / Cancer / Antineoplastic drugs / Cancer treatments / Signal transduction / Breast cancer / Macrolides / Eribulin / Halichondrin B / MTOR inhibitors / Eisai

EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i

DocID: 1rhhk - View Document

Immunosuppressants / Macrolides / Medicine / Clinical medicine / Sirolimus / Chemistry / Everolimus / Hives / Tacrolimus / Mechanistic target of rapamycin

The brain sirolimus pills. Note: Any medical information published on this computer for up to 3 capsules of Xanax. The brain. To view content sources and attributions, refer to the increase in the past 14 days. Wenn Sie

DocID: 1qxur - View Document

Medicine / Clinical medicine / Health / Macrolides / Immunosuppressants / Santen Pharmaceutical / Sirolimus / Central Drugs Standard Control Organization / Intravitreal administration / Mechanistic target of rapamycin

Microsoft Word - 20160704_Opsiria_India

DocID: 1q3TJ - View Document

Immunosuppressants / Pharmacokinetics / Macrolides / Tacrolimus

Beilage 1: Arzneimittelmonographien

DocID: 1oXt7 - View Document

Medicine / Clinical medicine / Immunology / Immunosuppressants / Macrolides / Signal transduction / Cancer treatments / Immunosuppressive drug / Sirolimus / Calcineurin / Tacrolimus / Cytokine

Microsoft PowerPoint - PhilNat-ClinImmunmodulation2016 handout [Kompatibilitätsmodus]

DocID: 1ogX3 - View Document